uniQure (NASDAQ:QURE – Get Free Report) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,180,000 shares, an increase of 22.8% from the June 30th total of 2,590,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio is presently 1.2 days.
Institutional Investors Weigh In On uniQure
A number of large investors have recently bought and sold shares of QURE. China Universal Asset Management Co. Ltd. raised its stake in uniQure by 222.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after buying an additional 4,315 shares during the period. SG Americas Securities LLC acquired a new stake in uniQure during the 2nd quarter worth $79,000. Vanguard Personalized Indexing Management LLC acquired a new stake in uniQure during the 4th quarter worth $86,000. Virtu Financial LLC acquired a new stake in uniQure during the 4th quarter worth $195,000. Finally, Clear Harbor Asset Management LLC increased its holdings in uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 12,500 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.
uniQure Price Performance
Shares of NASDAQ QURE traded down $0.23 during mid-day trading on Friday, reaching $8.34. The company had a trading volume of 733,674 shares, compared to its average volume of 7,658,339. The company has a 50-day moving average price of $5.75 and a two-hundred day moving average price of $5.48. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The stock has a market cap of $404.66 million, a PE ratio of -1.34 and a beta of 0.97.
uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. On average, equities analysts anticipate that uniQure will post -4.4 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts recently weighed in on QURE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. Mizuho cut their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $23.50.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.